Study on the therapeutic effect of four antituberculous regimens combined with the drug Moxifloxacin on tuberculous pleurisy
JIA Wen-cheng1 LU Guan-nan2▲
1.The Five Treatment Areas of Tuberculosis,the Fourth Hospital of Chaoyang City,Liaoning Province,Chaoyang 122000,China;
2.Department of Respiratory Medicine,Affiliated Hospital of Jilin Medical University,Jilin Province,Jilin 132013,China
Abstract：Objective To explore the therapeutic effect of the quadruple anti-tuberculosis program combined with the drug Moxifloxacin on tuberculous pleurisy.Methods A total of 48 cases of tuberculous pleurisy patients admitted to the Fourth Hospital of Chaoyang City from April 2017 to April 2018 were selected as the research objects,and were divided into the control group(24 cases)and the experimental group(24 cases)according to the random number table method.The control group was treated with a quadruple anti-tuberculosis regimen combined with conventional treatment,and the experimental group was treated with a quadruple anti-tuberculosis regimen combined with the drug Moxifloxacin.The immune function indicators of the two groups were compared,including the levels of T lymphocyte subsets CD8+,CD4+,CD4+/CD8+,and the levels of serum inflammatory factors including interferon-α(INF-α),interferon-γ(INF-γ),and interleukin 2(IL-2),interleukin 4(IL-4),interleukin 10(IL-10),clinical efficacy.Results The CD8+,CD4+,CD4+/CD8+,INF-γ,INF-α of the experimental group after treatment were higher than those of the control group,and the differences were statistically significant(P＜0.05).The IL-2,IL-4,IL-10 of the experimental group after treatment were lower than the control group,the differences were statistically significant(P<0.05).There were no significant difference in CD8+,CD4+,CD4+/CD8+,INF-γ,INF-α,IL-2,IL-4 and IL-10 between two groups before treatment(P>0.05).CD8+,CD4+,CD4+/CD8+,INF-γ,INF-α after treatment in the two groups were all higher than before treatment,and the differences were statistically significant(P<0.05).The IL-2,IL-4,and IL-10 levels of the two groups after treatment were lower than before treatment,and the differences were statistically significant(P<0.05).The total clinical effective rate(87.50%)of the experimental group was higher than that of the control group(54.16%),the difference was statistically significant(P<0.05).Conclusion The quadruple anti-tuberculosis regimen combined with the drug Moxifloxacin has a significant therapeutic effect in patients with tuberculous pleurisy,which can effectively inhibit the development of the disease and reduce adverse reactions.It is worthy of promotion and application.
贾文成；卢冠男. 四联抗结核方案联合药物莫西沙星对结核性胸膜炎的治疗作用研究[J]. 中国当代医药, 2021, 28(25): 159-162.
JIA Wen-cheng；LU Guan-nan. Study on the therapeutic effect of four antituberculous regimens combined with the drug Moxifloxacin on tuberculous pleurisy. 中国当代医药, 2021, 28(25): 159-162.
京公网安备 11010502046607号